Axonics Modulation Technologies - Gilde Healthcare

Axonics Modulation Technologies

Irvine (CA), USA
Next generation sacral neuromodulation
Since: 2017
Exit: 2018

US MedTech company focused on neuromodulation.

Axonics Modulation Technologies developed a novel and best-in-class sacral neuromodulation (SNM) system for the treatment of overactive bladder (OAB) and fecal incontinence. Axonics’ r-SNM is small (3cc), fully implantable, rechargeable, MRI compatible andworks in the body for up to 15 years. Axonics has CE Mark, FDA approval and is ramping sales throughout the US and Europe.
Axonics is now publicly listed on the NASDAQ under the ticker symbol AXNX.

More Axonics Modulation Technologies news

Axonics® expands into stress urinary incontinence with the acquisition of Bulkamid®

Axonics Modulation Technologies raises $130 million via public offering

Axonics® receives reimbursement approval in Germany for its Sacral Neuromodulation

Axonics® raises $110 million via Public Offering of Common Stock

Axonics® announces U.S. FDA approval for its sacral neuromodulation system for urinary clinical indications

Axonics® Provides Full One-Year Results from ARTISAN-SNM Pivotal Study at AUGS/IUGA Joint Scientific Meeting

Axonics receives FDA approval for neurostimulator to treat fecal incontinence

Axonics® Announces Fourth Quarter and Full Year 2018 Financial Results and Operational Update

Axonics® Submits Full Body MRI Data to U.S. Food & Drug Administration for its Sacral Neuromodulation System

Axonics raises $120 million via an Initial Public Offering on NASDAQ

Axonics® Announces $40 Million Financing

Axonics® Granted Seven New U.S. Patents Related to its Implantable Sacral Neuromodulation Technology

Axonics® Receives IDE Clearance from U.S. FDA to Conduct a Pivotal Study with its Sacral Neuromodulation System for the Treatment of Urinary Dysfunction

Positive Results for the Axonics® RELAX-OAB Clinical Study Presented at the International Continence Society Congress

Axonics(r) Appoints Dr. Karen L. Noblett as Chief Medical Officer

Gilde Healthcare participates in EUR 31 million financing round of neuromodulation company Axonics